Last Update 23 Apr 26
Fair value Increased 69%ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs.
Analyst Commentary
Bullish Takeaways
- Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease. They view this as central to supporting higher valuation multiples over time if clinical and regulatory milestones are met.
- Some bullish analysts point to a planned MASH pivotal program and a Phase 3 registrational design under Subpart H as important steps. These could clarify the path to potential commercialization and make cash flows easier to model.
- Analysts citing a pro forma cash position of about US$340m view this as providing a meaningful runway for Phase 2 and Phase 3 work. They see this as reducing near term financing risk in their models.
- Upcoming Phase 2 RECLAIM AUD topline data and other alcohol-related disease readouts are seen by bullish analysts as key catalysts. These could support higher earnings assumptions and justify richer P/E inputs in fair value work.
Bearish Takeaways
- More cautious analysts highlight that formal Phase 3 execution for MASH and the registrational program is still ahead. They see meaningful execution risk before any potential revenue can be realized.
- The reliance on encouraging clinical and preclinical liver data means valuation is sensitive to any mixed or weaker than expected results. This could prompt lower P/E and revenue assumptions in future models.
- Some investors may view the reaction to company updates, including an 18% intraday sell off referenced by analysts, as a sign that sentiment can swing sharply around news. This introduces volatility into fair value estimates.
- With multiple programs and indications in play, cautious analysts flag the risk that timelines, trial design changes, or regulatory feedback could affect modeled cash burn and the perceived adequacy of the US$340m cash runway.
What's in the News
- The White House is preparing a waiver to allow E15 gasoline sales during the summer driving season, which can affect demand patterns for ethanol producers such as Alto Ingredients (Bloomberg).
- The company reported that from October 1, 2025 to December 31, 2025, it did not repurchase additional shares under its buyback program, with 0 shares repurchased for US$0 million in that period.
- Alto Ingredients has completed its previously announced buyback, repurchasing 2,552,377 shares, or 3.37% of shares, for a total of US$6.04 million under the program announced on September 12, 2022.
Valuation Changes
- Fair Value: The analyst fair value estimate has risen from $4.00 to $6.75 per share.
- Discount Rate: The discount rate has decreased from 10.49% to 7.72%, reflecting updated risk assumptions in analyst models.
- Revenue Growth: The long-term revenue growth assumption has been reduced from 3.73% to 2.47%.
- Net Profit Margin: The net profit margin assumption has been lowered from 9.45% to 4.18%.
- Future P/E: The future P/E multiple assumption has increased from 4.33x to 15.73x.
Key Takeaways
- Tax credit extensions and regulatory shifts favor Alto, enhancing profitability, market positioning, and supporting revenue and margin growth through renewable fuels and premium exports.
- Strategic acquisitions, operational improvements, and sustained cost-efficiency measures are strengthening margins, earnings quality, and enabling scalable growth in higher-value, lower-carbon products.
- Heavy reliance on volatile ethanol markets, policy incentives, and outdated technology exposes the company to earnings instability, competitive pressures, and long-term demand erosion risks.
Catalysts
About Alto Ingredients- Produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States.
- The extension and expansion of the 45Z federal tax credit for domestic renewable fuels through 2029, combined with Alto's ongoing initiatives to lower carbon intensity at its plants, is expected to significantly enhance profitability and cash flows over the next several years-estimated to provide at least $18 million in incremental earnings opportunity across two major facilities by 2026, boosting both net margins and intrinsic asset value.
- Increasing regulatory focus on supporting U.S. grown feedstock and higher ethanol blend requirements, as well as tightening eligibility criteria for credits (favoring domestic producers), positions Alto Ingredients to benefit from a growing global and domestic market for renewable fuels, supporting future revenue growth.
- Alto's successful expansion into the European ISCC export market for higher-margin, high-quality alcohols is already driving incremental revenue, while capacity for further growth remains-and strategic investments to repair infrastructure (like the dock) will enable sustained growth in premium exports, supporting both revenue and margin improvement.
- The Carbonic acquisition and operational improvements at key plants have led to markedly higher CO2 production and utilization, with synergies and further upside yet to be realized; continued optimization is expected to drive additional gross profit and increase overall EBITDA sustainability.
- Ongoing overhead reduction initiatives and cost-efficiency measures, which are exceeding annualized savings targets, will continue to lower SG&A and COGS, providing lasting improvement in operating leverage and thus enhancing earnings quality and scalability as Alto realigns toward higher-value, lower-carbon product lines.
Alto Ingredients Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Alto Ingredients's revenue will grow by 2.5% annually over the next 3 years.
- Analysts assume that profit margins will increase from 1.3% today to 4.2% in 3 years time.
- Analysts expect earnings to reach $41.3 million (and earnings per share of $0.53) by about April 2029, up from $12.1 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.8x on those 2029 earnings, down from 33.1x today. This future PE is lower than the current PE for the US Chemicals industry at 29.6x.
- Analysts expect the number of shares outstanding to grow by 0.11% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.72%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Persistent operational volatility, evidenced by recurring losses (Q2 2025 net loss of $11.3 million versus $3.4 million in Q2 2024) and negative adjusted EBITDA, exposes Alto Ingredients to risks of structurally low earnings and limited capacity to deliver sustainable net margin improvement in a highly competitive industry.
- Continued overreliance on commodity fuel ethanol sales (with fewer gallons sold at lower prices in Q2 2025), alongside high sensitivity to crush margins and derivative swings, suggests ongoing exposure to the secular trend of declining internal combustion engine demand and transportation electrification, threatening long-term core revenue streams.
- The company's dependence on governmental incentives-especially 45Z credits expiring in 2029 and regulations that may shift toward non-corn-based or next-generation biofuels-presents vulnerability to policy change or erosion of support for conventional corn ethanol, which could negatively impact both revenue and earnings predictability.
- Intensifying competition in the specialty alcohol and ingredients market (noted by falling high-value alcohol premiums and margin compression in Q2), along with limited historical investment in proprietary technology or brand differentiation, risks Alto's ability to offset declining margins in its traditional segments, thereby constraining future top-line growth.
- Input cost volatility, particularly with rising commodity reference prices for corn and soybeans and uncertainty surrounding sustainable low-carbon feedstock sourcing, could lead to higher cost of goods sold and margin contraction-especially if climate impacts further tighten supply-pressuring gross and net margins longer-term.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $6.75 for Alto Ingredients based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $5.5.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $987.5 million, earnings will come to $41.3 million, and it would be trading on a PE ratio of 15.8x, assuming you use a discount rate of 7.7%.
- Given the current share price of $5.17, the analyst price target of $6.75 is 23.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Alto Ingredients?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.